Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA et al (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36: 71–93.
Carstensen B, Kristensen JK, Ottosen P, Borch-Johnsen K (2008). The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia 51: 2187–2196.
Cohen D (2006). Diabetes mellitus in schizophrenia or schizoaffective disorder: an iatrogenic or endogenic problem? (thesis), Haarlem, Netherlands. ISBN: 90-808509-3-4.
De Hert M, Detraux J, van Winkel R, Correll C (2011). Antipsychotic medications: metabolic, cardiovascular and cardiac risks. Nature Rev Endocr (in press).
Nielsen J, Skadhede S, Correll CU (2010). Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 35: 1997–2004.
Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Asenjo Lobos C et al (2010). Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123: 225–233.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr Cohen has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory boards of Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Jansen Cilag. Dr M de Hert has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory boards of Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck JA, Pfizer, and Sanofi Aventis.
Rights and permissions
About this article
Cite this article
Cohen, D., De Hert, M. Endogenic and Iatrogenic Diabetes Mellitus in Drug-naïve Schizophrenia: The Role of Olanzapine and its Place in the Psychopharmacological Treatment Algorithm. Neuropsychopharmacol 36, 2368–2369 (2011). https://doi.org/10.1038/npp.2011.94
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2011.94
This article is cited by
-
Polygenic risk for schizophrenia and bipolar disorder in relation to cardiovascular biomarkers
European Archives of Psychiatry and Clinical Neuroscience (2023)
-
Diabetogenic Effects Associated with Psychiatric Treatment
Current Pharmacology Reports (2018)
-
Aminotransferase levels as a prospective predictor for the development of metabolic syndrome in patients with schizophrenia
Psychopharmacology (2014)
